Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation

by Hua Jing, Michael Hettich, Simone Gaedicke, Elke Firat, Mark Bartholomä, Gabriele Niedermann
Published 2019-02-01

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Fa...

by Florian Rosar, Hanna Bader, Mark Bartholomä, Stephan Maus, Caroline Burgard, Johannes Linxweiler, Fadi Khreish, Samer Ezziddin
Published 2022-05-01

Renal Safety of [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function

by Florian Rosar, Niklas Kochems, Mark Bartholomä, Stephan Maus, Tobias Stemler, Johannes Linxweiler, Fadi Khreish, Samer Ezziddin
Published 2021-06-01

Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients

by Florian Rosar, Kalle Ribbat, Martin Ries, Johannes Linxweiler, Mark Bartholomä, Stephan Maus, Mathias Schreckenberger, Samer Ezziddin, Fadi Khreish
Published 2020-05-01

Response Assessment and Prediction of Progression-Free Survival by ⁶⁸Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</su...

by Fadi Khreish, Mona Wiessner, Florian Rosar, Zaidoon Ghazal, Amir Sabet, Stephan Maus, Johannes Linxweiler, Mark Bartholomä, Samer Ezziddin
Published 2021-07-01

Efficacy and Safety of [²²⁵Ac]Ac-PSMA-617 Augmented [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

by Florian Rosar, Jonas Krause, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Samer Ezziddin, Fadi Khreish
Published 2021-05-01

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy

by Florian Rosar, Niklas Schön, Hendrik Bohnenberger, Mark Bartholomä, Tobias Stemler, Stephan Maus, Fadi Khreish, Samer Ezziddin, Andrea Schaefer-Schuler
Published 2021-05-01

Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker

by Caroline Burgard, Jakob Engler, Arne Blickle, Mark Bartholomä, Stephan Maus, Andrea Schaefer-Schuler, Fadi Khreish, Samer Ezziddin, Florian Rosar
Published 2024-01-01

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC

by Florian Rosar, Robert Neher, Caroline Burgard, Johannes Linxweiler, Mathias Schreckenberger, Manuela A. Hoffmann, Mark Bartholomä, Fadi Khreish, Samer Ezziddin
Published 2022-03-01

Value of Combined PET Imaging with [¹⁸F]FDG and [⁶⁸Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [¹⁷⁷Lu]Lu-PSMA-617 RLT

by Fadi Khreish, Kalle Ribbat, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Mathias Schreckenberger, Samer Ezziddin, Florian Rosar
Published 2021-08-01

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations

by Caroline Burgard, Florian Rosar, Robert J. Marlowe, Mark Bartholomä, Sebastian Dewes, Andrea Schaefer-Schuler, Johannes Linxweiler, Fadi Khreish, Samer Ezziddin
Published 2023-05-01

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT

by Florian Rosar, Caroline Burgard, Scott David, Robert J. Marlowe, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer-Schuler, Samer Ezziddin
Published 2024-05-01

[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis

by Florian Rosar, Caroline Burgard, Elena Larsen, Fadi Khreish, Robert J. Marlowe, Andrea Schaefer-Schuler, Stephan Maus, Sven Petto, Mark Bartholomä, Samer Ezziddin
Published 2024-02-01

Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer

by Cordula A. Jilg, Kathrin Reichel, Christian Stoykow, H. Christian Rischke, Mark Bartholomä, Vanessa Drendel, Moritz von Büren, Wolfgang Schultze-Seemann, Philipp T. Meyer, Michael Mix
Published 2020-03-01

Radiochemistry and Preclinical PET Imaging of Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen

by Eleni Gourni PhD, Luigi Del Pozzo BSc, Mark Bartholomä PhD, Yvonne Kiefer BSc, Philipp T. Meyer MD, PhD, Helmut R. Maecke PhD, Jason P. Holland D.Phil
Published 2017-10-01